# Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

> **NCT04737265** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 101 (actual)

## Conditions studied

- Cardiotoxicity
- Toxicity Due to Chemotherapy
- Breast Cancer
- Lymphoma
- Cardiomyopathies
- Heart Failure

## Interventions

- **OTHER:** Biomarker Guided Intervention

## Key facts

- **NCT ID:** NCT04737265
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-18
- **Primary completion:** 2025-02-05
- **Final completion:** 2025-02-05
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04737265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04737265, "Pilot Study of an NTproBNP Guided Strategy of Cardioprotection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04737265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*